Technology
Health
Biotechnology

Novelion Therapeutics

$1.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (2.59%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NVLN and other stocks, options, ETFs, and crypto commission-free!

About

Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. Read More The company was founded on February 3, 1981 and is headquartered in Vancouver, Canada.

Employees
109
Headquarters
Vancouver, British Columbia
Founded
1981
Market Cap
22.66M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
669.71K
High Today
$1.19
Low Today
$1.16
Open Price
$1.16
Volume
20.02K
52 Week High
$4.79
52 Week Low
$0.70

Collections

Technology
Health
Biotechnology
Therapy
Canada
North America

News

Yahoo FinanceMay 7

Novelion Therapeutics Reports First Quarter 2019 Financial Results

Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia, and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2019. Novelio...

79

Earnings

-$1.49
-$0.94
-$0.40
$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.15 per share
Actual
$0.10 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.